The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis

Kang, Yi‐No; Chi, Sheng-Chu; Wu, Mei‐Hwan; Chiu, H. H.

doi:10.1016/j.jfma.2019.03.018

Cited by 17 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This comprehensive review team consisting of nephrologists and an experienced researcher conducted this study according to the Cochrane handbook, and reported the systematic review and meta-analysis according to the PRISMA guidelines [76]. The experienced researcher previously participated in some studies about nutrient, internal medicine, and chronic kidney disease [77,78,79,80]. The researcher also has some experience in conducting network meta-analysis [81,82].…”

Section: Methodsmentioning

confidence: 99%

Efficacy of Polyunsaturated Fatty Acids on Inflammatory Markers in Patients Undergoing Dialysis: A Systematic Review with Network Meta-Analysis of Randomized Clinical Trials

Yeh

et al. 2019

IJMS

Self Cite

View full text Add to dashboard Cite

The effects of polyunsaturated fatty acids (PUFAs) on inflammatory markers among patients receiving dialysis have been discussed for a long time, but previous syntheses made controversial conclusion because of highly conceptual heterogeneity in their synthesis. Thus, to further understanding of this topic, we comprehensively gathered relevant randomized clinical trials (RCTs) before April 2019, and two authors independently extracted data of C-reactive protein (CRP), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) for conducting network meta-analysis. Eighteen eligible RCTs with 962 patients undergoing dialysis were included in our study. The result showed that with placebo as the reference, PUFAs was the only treatment showing significantly lower CRP (weighted mean difference (WMD): −0.37, 95% confidence interval (CI): −0.07 to −0.68), but the CRP in PUFAs group was not significantly lower than vitamin E, PUFAs plus vitamin E, or medium-chain triglyceride. Although no significant changes were noted for hs-CRP and IL-6 levels, PUFAs showed the best ranking among treatments according to surface under the cumulative ranking. Therefore, PUFAs could be a protective option for patients receiving dialysis in clinical practice.

show abstract

Section: Methodsmentioning

confidence: 99%

Efficacy of Polyunsaturated Fatty Acids on Inflammatory Markers in Patients Undergoing Dialysis: A Systematic Review with Network Meta-Analysis of Randomized Clinical Trials

Yeh

et al. 2019

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similar hypothesis was formulated by the authors of a double-blind trial in MFS adults (n=34) treated for 6 months with losartan (100 mg QD) or atenolol (50 mg QD). Indeed, pulse wave velocity (PWV) decreased in atenolol group (-1. inferior to β-blocker therapy, and that co-treatment with ARB seemed to be favourable to those of only β-blocker therapy [108].…”

Section: β-Blockers and Arbs In Marfan's Syndrome (Mfs)mentioning

confidence: 96%

Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?

Castiglioni

Camera

Sironi

2020

Biochemical Pharmacology

View full text Add to dashboard Cite

“…Currently, a meta-analysis reported that only-AT1 receptor blocker therapy is not inferior to only-β-blocker therapy for cardiovascular protection in MFS. Besides, the outcomes of AT1 receptor blocker-plus-β-blocker therapy seemed to be favorable than only-β-blocker therapy [ 38 ].…”

Section: T Reatment For Cardiovascular Manifestationsmentioning

confidence: 99%

An update of medical care in Marfan syndrome

Chiu¹

2022

Tzu Chi Medical Journal

Self Cite

View full text Add to dashboard Cite

Marfan syndrome (MFS), a multisystemic connective disorder, caused by fibrillin 1 gene mutations with autosomal dominant inheritance. The disease spectrum is wide and the major causes of death are related to aortic root aneurysm or dissection. The purposes of medical treatment are to reduce structural changes in the aortic wall and slow aortic root dilatation. Advance in medical researches have provided new insights into the pathogenesis of disease and opened up new horizons for treatments. Several medications such as angiotensin II type I receptor blockers, β-blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, tetracyclines, and statins have been studied for the purpose. Currently, the life expectancy of Marfan patients improves significantly and is closes to the general population with proper treatment. In this article, we review and update the medical treatments for patients with MFS.

show abstract

The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis

Cited by 17 publications

References 29 publications

Efficacy of Polyunsaturated Fatty Acids on Inflammatory Markers in Patients Undergoing Dialysis: A Systematic Review with Network Meta-Analysis of Randomized Clinical Trials

Efficacy of Polyunsaturated Fatty Acids on Inflammatory Markers in Patients Undergoing Dialysis: A Systematic Review with Network Meta-Analysis of Randomized Clinical Trials

Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?

An update of medical care in Marfan syndrome

Contact Info

Product

Resources

About